Cautious Optimism As Genentech/AC Immune’s Anti-Tau Antibody Slows Cognitive Decline

Next Steps May Depend On Longer-Term Open-Label Data

 
• By Mandy Jackson
  
Tau protein in Alzheimer's disease
AC Immune's CEO said semorinemab efficacy in mild-to-moderate Alzheimer's disease may relate to the tau species the antibody targets • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D